See page 3 for an interactive table of contents to easily navigate your way through this guide.

DON’T MISS THE VIRTUAL EXHIBIT HALL
Exhibits are open daily Nov. 13-15, 2021, and will be accessible OnDemand through Dec. 15, 2021.

scientificsessions.org
Are you taking advantage of your AHA member benefits?

3 opportunities to save!

1. Add print subscriptions to your membership for just $225 per journal (domestic or international)
2. Get 30% off + free shipping when you order essential Wolters Kluwer books at AHA Scientific Sessions 2021
3. Buy Wolters Kluwer books at a 30% discount throughout the year

Buy Wolters Kluwer books at shop.lww.com/aha
Welcome to #AHA21
5  Message from the Chair
6  Schedule at a Glance
8  Virtual Event Highlights

Programming
11  Main Events
13  Late-Breaking Science
17  Programming Communities
18  Learning Studios
22  OnDemand
23  ReSS at Sessions
23  QCOR at Sessions
24  Symposia Schedule
26  Center for Health Technology & Innovation
27  Frontiers in Science Summit

Early Career
28  Early Career Programming
29  Early Career Clinical Case Competition
31  Early Career On-Demand
32  Networking at Scientific Sessions 2021

Exhibitors
33  Exhibitor information
44  Product Categories
46  Exhibitors by Community
49  Scientific Sessions 2021 Supporters

Join the Conversation
Facebook.com/AHAMeetings
@AHAMeetings @AHAScience
Youtube.com/user/AHAScienceNews
#AHA21 #RESS21 #QCOR21

Stay Connected
See page 9 for complete information about the Mobile Meeting Guide App and Scavenger Hunt.

American Heart Association
National Center
7272 Greenville Ave.
Dallas, TX 75231
214-373-6300
800-242-2453
professional.heart.org

© 2021 American Heart Association. All rights reserved.

Publishing partner for Scientific Sessions 2021: Ascend Media LLC ascendmedia.com 913-469-1110

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be held responsible for errors or omissions. Data current as of Oct. 31, 2021.
JOIN US FOR A Virtual Symposium at the Scientific Sessions 2021

PRESENTERS:

Mat Maurer, MD
Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University
Irving Medical Center
New York Presbyterian Hospital

Alanna A. Morris MD, MSc, FHFSA, FACC, FAHA
Associate Professor of Medicine, Division of Cardiology
Director of Heart Failure Research
Emory University Clinical Cardiovascular Research Institute

Kevin M. Alexander,
MD, FACC, FHFSA
Assistant Professor of Medicine,
Advanced Heart Failure and Transplant Cardiology
Stanford Amyloid Center,
Stanford University

Keyur B. Shah, MD
David E. Tolman Professor in Heart Failure
Section Chief, Heart Failure
Virginia Commonwealth Univ. Health

Hidden in Plain Sight: ATTR CM in Overlooked Patient Populations

Sunday, November 14th
7:30pm - 9:00pm EST

AND ON DEMAND

In this symposium we will discuss the prevalence of ATTR-CM in Black Americans and in subpopulations with HFpEF, addressing biological and genetically inherited differences, implicit bias, and healthcare challenges that may disproportionately impact the diagnosis and treatment of those groups.

We look forward to you joining the discussion!

This event is not part of the official Scientific Sessions 2021 as planned by the AHA Committee on Scientific Sessions Programming.
Welcome

It is my great pleasure to welcome you to the American Heart Association’s Scientific Sessions 2021. This year’s meeting is centered around renewed connections and passionate discussions on the year’s most ground-breaking updates in the fields of cardiovascular clinical, basic and population science.

Regardless of your location, you have the opportunity to participate in group discussions and debates, engage with interactive sessions featuring cutting-edge topics across an array of specialties, and meaningfully connect with peers, mentors and friends from around the world.

The scope and quality of the scientific exchange is what makes AHA Scientific Sessions the premier cardiovascular research and instructional meeting in the world.

- Watch as the most highly anticipated breakthroughs in patient care are announced during Late Breaking Science sessions.
- Immerse yourself in cutting-edge CV science topics during our Main Event sessions.
- Stay on top of the latest trends in health care technology with the 3-day Health Tech & Innovative offerings.
- Over 400 sessions including subspecialty and cross-specialty programming, and 4,000 abstracts!
- Engage with the world’s resuscitation science elite at the 3-day Resuscitation Science Symposium (ReSS).
- Connecting with colleagues has never been easier with numerous ways to engage your colleagues.

So, please join in on the conversation happening online by following #AHA21. I can’t wait to see you there!

Sincerely yours,

Manesh R. Patel, MD, FAHA
Chair, Committee on Scientific Sessions Program
Experience #AHA21

Meet us online (via the Scientific Sessions 2021 virtual platform) for the global cardiovascular event of the year. At Scientific Sessions 2021, Nov. 13-15, experience breakthrough cardiovascular basic, clinical and population science updates, reconnect with colleagues and immerse yourself in innovative solutions designed to help you in your daily practice.

In this unprecedented year, the AHA is offering its Scientific Sessions programming in ways that let you define your programming experience thanks to our interactive, fully virtual event. You can enjoy Featured Sessions, Multidisciplinary Sessions and On-Demand Content with the same registration.

### VIRTUAL SCHEDULE AT A GLANCE #AHA21

<table>
<thead>
<tr>
<th>SATURDAY</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 13</td>
</tr>
<tr>
<td>6:00 AM EST – 8:00 AM EST</td>
</tr>
<tr>
<td>Satellite Events Networking Activities</td>
</tr>
<tr>
<td>8:00 AM EST – 12:00 PM EST</td>
</tr>
<tr>
<td>Opening Session</td>
</tr>
<tr>
<td>Main Events Late-Breaking Science Industry Events Networking Activities Special Programming*</td>
</tr>
<tr>
<td>12:00 PM EST – 6:00 PM EST</td>
</tr>
<tr>
<td>Main Events Late-Breaking Science Industry Events Networking Activities Special Programming*</td>
</tr>
<tr>
<td>6:00 PM EST – 8:30 PM EST</td>
</tr>
<tr>
<td>Satellite Events Networking Activities</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SUNDAY</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 14</td>
</tr>
<tr>
<td>6:00 AM EST – 8:00 AM EST</td>
</tr>
<tr>
<td>Satellite Events Networking Activities</td>
</tr>
<tr>
<td>8:00 AM EST – 12:00 PM EST</td>
</tr>
<tr>
<td>Main Events Late-Breaking Science Industry Events Networking Activities Special Programming*</td>
</tr>
<tr>
<td>12:00 PM EST – 6:00 PM EST</td>
</tr>
<tr>
<td>Presidential Session (1 PM)</td>
</tr>
<tr>
<td>Main Events Late-Breaking Science Industry Events Networking Activities Special Programming*</td>
</tr>
<tr>
<td>6:00 PM EST – 8:30 PM EST</td>
</tr>
<tr>
<td>Satellite Events Networking Activities</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MONDAY</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 15</td>
</tr>
<tr>
<td>6:00 AM EST – 8:00 AM EST</td>
</tr>
<tr>
<td>Satellite Events Networking Activities</td>
</tr>
<tr>
<td>8:00 AM EST – 12:00 PM EST</td>
</tr>
<tr>
<td>Main Events Late-Breaking Science Industry Events Networking Activities Special Programming*</td>
</tr>
<tr>
<td>12:00 PM EST – 5:30 PM EST</td>
</tr>
<tr>
<td>Networking Activities</td>
</tr>
<tr>
<td>5:30 PM EST – 9:00 PM EST</td>
</tr>
<tr>
<td>Networking Activities</td>
</tr>
</tbody>
</table>

*Early Career & FIT, Women in Science & Medicine programming
ReSS at Sessions | November 12-14
QCOR at Sessions | November 15
ePosters | Exhibits | OnDemand Content
Scientific Sessions 2021 will be a highly interactive online experience. This is your chance to participate in the ground-breaking discussions while also enjoying your favorite #AHA21 benefits included in the online offering:

- Live and On-Demand sessions across 27 communities covering Basic, Clinical and Population science
- Real connections, real conversations at your fingertips
- Presentations by global thought leaders
- Personalized education for CE and MOC credits
- Exclusive council activities, awards and recognition

Enjoy access to leaders in the field and uncover the latest discoveries in cardiovascular science and medicine. You can also reconnect and collaborate with global thought leaders from all over the world.

Your Scientific Sessions registration also gives you access to the Resuscitation Science Symposium (ReSS), which takes place Nov. 12-14, and the Quality of Care and Outcomes Research (QCOR Conference) on Nov. 15.
Download the free Mobile Meeting Guide App

Get instant access to educational sessions, faculty, abstracts, event schedule, and exhibitors.

Compete in the Scientific Sessions 2021 scavenger hunt!
Hunt for QR codes on featured sessions, exhibitor pages and networking events to earn points for prizes.

Exhibitors
Sessions
Networking

Search “AHA Conferences”

Sponsored by Novartis
Visit the Exhibit Hall

Exhibits are open daily Nov. 13-15, 2021.

Simulation and educational demonstrations

Meet exhibitors in virtual meetings

Exhibitor AI Matchmaking
### Saturday, Nov. 13

**9:30 a.m. EST**
- Managing Stable CAD in a Post-Ischemia World
- Cardio-Oncology: From a Science Journey to a Patient Journey

**11 a.m. EST**
- Novel Strategies to Promote Healthy Vascular Aging
- Cardiovascular Health After 10 Years: What Have We Learned, and What is the Future?
- ACC/AHA Valvular Heart Disease Guidelines: What You Need to Know and What Comes Next

**3 p.m. EST**
- Atrial Fibrillation in 2021: Prepare for New Directions
- 2021 Dietary Guidance to Improve Cardiovascular Health

**4:30 p.m. EST**
- COVID Vaccine Development and CVD Implications: Updates and Fireside Chat
- Organ on Demand: 3D Printing for CVD
- Structuring the Future: Planning and Imaging of Structural Heart Interventions

### Sunday, Nov. 14

**8 a.m. EST**
- Paul Dudley White International Lecture and Session
- War on Pulmonary Embolism: Ending Complacency in the Face of Critical Clinical and Research Challenges

**9:30 a.m. EST**
- Science Catalyst Keynote and Thomas Smith Memorial Lecture
- Achieving Health Equity: Advancing to Solutions
- Rapid Fire Results From AHA Research on COVID-19

**3:30 p.m. EST**
- Where Should New Heart Failure Guidelines Change in 2021?
- Distinguished Scientist Lecture

**5 p.m. EST**
- Single Cell Profiles in Cardiovascular Diseases

### Monday, Nov. 15

**8 a.m. EST**
- Digital Impact on Disparities in Cardiovascular Care: Can Big Tech Step up to the Challenge?
- Singling Out Cardiac Fibrosis and Regeneration: Insights From Single Cell Biology

**9:30 a.m. EST**
- Chest Pain Guidelines
- Long-Term COVID-19: Cardiopulmonary Translational Science
- Intersection Between Academic Role in Basic Science and Industry

**11 a.m. EST**
- Confronting the Tide of Heart Failure in Diabetes: From Mechanisms to Management
- The Dr. Nanette K. Wenger Research Goes Red® Award

**3 p.m. EST**
- Closing Session: Trending Topics at AHA 2021
Authoritative, Multidisciplinary Coverage of This Rapidly Evolving Field — Written by Clinicians, for Clinicians

Covering every area relevant to the daily practice of cardiovascular medicine, *Cardiovascular Medicine and Surgery* brings together a stellar team of cardiovascular specialists who focus on cutting-edge strategies for the clinical and surgical management of patients.

Additional Essential Cardiology Resources

Order Today!
Scan the QR code or visit Shop.lww.com/AHA_WK2021

Save 30% + FREE SHIPPING!
Use promo code WMA409AA at checkout.
Late-Breaking Science

Saturday, Nov. 13

9:30-10:30 a.m. EST
LBS.01 | Valves, Veins and New Viewpoints in Cardiothoracic Surgery
• Aortic Valve Replacement Versus Watchful Waiting in Asymptomatic Severe Aortic Stenosis: The Avatar Trial (AVATAR)
• Evaluating the Benefit of Concomitant Tricuspid Repair During Mitral Valve Surgery
• A Randomized Study of Early Versus Standard Coronary Artery Bypass Surgery Among Patients Presenting With Acute Coronary Syndromes Treated With Ticagrelor (RAPID CABG)
• Efficacy and Safety of an External Support Device for Saphenous Vein Coronary Bypass Grafts: The VEST Trial (VEST)

3-4 p.m. EST
LBS.02 | Hypertension: Local, Global and Pandemic Impacts
• A Remotely Delivered Hypertension and Lipid Program in 10,000 Patients Across a Diverse Health Care Network
• Disruption in Blood Pressure Control With the COVID-19 Pandemic: A Study of 24 U.S. Health Systems in the Pcornet Blood Pressure Control Laboratory (BP Track)
• A Cluster Randomized Trial of a Village Doctor-led Intervention on Blood Pressure Control: China Rural Hypertension Control Project (CRHCP)
Sunday, Nov. 14

8-9 a.m. EST
LBS.03 | Prevention to Intervention in Atrial Arrhythmias
- The Coffee and Real-time Atrial and Ventricular Ectopy (CRAVE) Trial (CRAVE)
- Dabigatran Versus Warfarin on Cognitive Outcomes in Nonvalvular Atrial Fibrillation: Results of The GIRAF Trial (GIRAF)
- Posterior Left Pericardiectomy Reduces Postoperative Atrial Fibrillation After Cardiac Surgery (PALACS)
- Outcomes of Adjunctive Left Atrial Appendage Ligation Utilizing the LARIAT Compared to Pulmonary Vein Antral Isolation Alone: The AMAZE Trial (AMAZE)

2:45 pm - 3:45 p.m. EST
LBS.04 | Information Overload? Striving to Improve Care Delivery Through Digital Health and Automated Data
- Risk Evaluation and its Impact on Clinical Decision Making and Outcomes in Heart Failure: The REVeAL-HF Trial (REVeAL-HF)
- Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study
- Testing Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial (I-STOP-AFib)

4-5 p.m. EST
LBS.05 | Building on the Foundations of Treatment: Advances in Heart Failure Therapy
- Empagliflozin in Heart Failure With a Preserved Ejection Fraction >50% - Results From the EMPEROR-Preserved Clinical Trial (EMPEROR-Preserved)
- The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Clinical Trial (CHIEF-HF)
- Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results From the EMPULSE Trial (EMPULSE)
- Randomized Trial of Targeted Transendocardial Delivery of Mesenchymal Precursor Cells in High-Risk Chronic Heart Failure Patients With Reduced Ejection Fraction (DREAM-HF)

Monday, Nov. 15

8-9 a.m. EST
LBS.06 | Fish Oil, Cocoa and Cholesterol: Recipes for CVD Prevention?
- Icosapent Ethyl Versus Placebo in Outpatients With COVID-19: The Main Results of PREPARE-IT 2 (PREPARE-IT 2)
- The Clinical Safety, Pharmacokinetics, and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor

11 a.m.-Noon EST
LBS.07 | New Drugs and New Drug Indications in Cardiovascular Disease
- Effects Of Aspirin on Dementia and Cognitive Impairment in the ASCEND Trial (ASCEND)
- P2y12 Inhibitors in Noncritically Ill Hospitalized Patients With COVID-19 (ACTIV-4A)
- Effect Of Bentracimab on Platelet Inhibition and Hemostasis in Ticagrelor Patients With Uncontrolled Hemorrhage or Requiring Urgent Surgery in the REVERSE-IT (REVERSE-IT)
- Milvexian for Prevention of Venous Thromboembolism After Elective Knee Arthroplasty: The AXIOMATIC-TKR Study (AXIOMATIC-TKR)

Don't forget to visit the virtual Exhibit Hall for the latest in Science & Technology
Abstracts on Download

One download. Thousands of abstracts.

Download your complimentary copy today.

Made possible in part through support by Janssen Pharmaceuticals, Inc.
Visit the ePosters

Thousands of posters, including moderated digital poster sessions available each day of the virtual experience.

Made possible in part through support by Bristol Myers Squibb
Scientific Sessions 2021 provides science for everyone, offering the global educational experience to improve cardiovascular health, champion scientific discovery and innovate clinical practice.

Sessions feature the most impactful breakthroughs and discussions in a broad array of topics. To tailor your search in the **Online Program Planner**, click the links below.

<table>
<thead>
<tr>
<th>Basic Science</th>
<th>Clinical Science</th>
<th>Population Science</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Arteriosclerosis, Thrombosis, Vascular Biology</td>
<td>• Acute Coronary Syndromes</td>
<td>• Cardiometabolic Health and Diabetes</td>
</tr>
<tr>
<td>• Cardiac Development, Structure and Function</td>
<td>• Cardio-Oncology</td>
<td>• COVID-19</td>
</tr>
<tr>
<td>• Cellular Biology</td>
<td>• Congenital Heart Disease and Pediatric Cardiology</td>
<td>• Cross Specialty</td>
</tr>
<tr>
<td>• COVID-19</td>
<td>• COVID-19</td>
<td>• Epidemiology, Big Data and Precision Medicine</td>
</tr>
<tr>
<td>• Cross Specialty</td>
<td>• Cross Specialty</td>
<td>• GRFW and Special Populations</td>
</tr>
<tr>
<td>• Drug Discovery</td>
<td>• Electrophysiology and Arrhythmias</td>
<td>• Health Tech</td>
</tr>
<tr>
<td>• Genetics and Genomics</td>
<td>• Heart Failure and Cardiomyopathies</td>
<td>• Lifestyle &amp; Behavioral Medicine</td>
</tr>
<tr>
<td>• Metabolism and Physiology</td>
<td>• Hypertension and Nephrology</td>
<td>• Prevention, Health and Wellness</td>
</tr>
<tr>
<td>• Signaling</td>
<td>• Imaging and Nuclear Medicine</td>
<td>• Quality of Care and Outcomes Research</td>
</tr>
<tr>
<td></td>
<td>• Interventional Treatments</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Nursing Research and Clinical</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Pulmonary Hypertension and Critical Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Resuscitation Science Symposium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ReSS at Sessions</td>
<td>Nov. 12-14</td>
</tr>
<tr>
<td></td>
<td>• Stroke &amp; Neuroscience</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Surgery &amp; Anesthesia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Vascular Disease and Thrombosis</td>
<td></td>
</tr>
</tbody>
</table>

The **Online Program Planner** allows you to search sessions by Day, Session Type and Track, making it easier to plan your schedule. Please visit the Online Program Planner frequently for the most current programming.
Saturday, Nov. 13

11-11:45 a.m. EST

The Heart of the Matter: A New Treatment for Slowing CKD Progression and Reducing CV Risk in Patients With CKD Associated With T2D
Recent advancements in clinical understanding of CKD associated with T2D and accompanying cardiovascular risk have informed new treatment options and strategies for disease management. This event will showcase a new prescription treatment for CKD associated with T2D and present clinical safety and efficacy data for this treatment. How to identify appropriate adult patients with CKD associated with T2D and how to initiate treatment will also be discussed. After the presentation, there will be an opportunity for Q&A.
Supporter: Bayer HealthCare Pharmaceuticals Inc.

Heart Failure Isn’t the Only Type of Failure in Cardiology: Addressing the Misdiagnosis of HCM
Experts will explore challenging HCM patient cases, highlight clinical findings that should raise the index of suspicion for HCM among alternative diagnoses and discuss available imaging modalities and additional resources to help eliminate HCM misdiagnosis altogether
Supporter: Bristol Myers Squibb

11 a.m.-12:30 p.m. EST

Potential Impact of Virtual Longitudinal Studies
Mobile devices, wearable technology and easier patient access to health records provide opportunities for scaled, decentralized research that captures data from a host of different sources. The use of technology removes barriers to participation, increases access to traditionally under-represented groups, and results in the seamless generation
and collection of data. With that in mind, AHA will bring together key thought leaders in the cardiovascular and digital health space to discuss the changing landscape of virtual trials and studies, along with the benefits and challenges in accelerating research and ultimately improving health outcomes.

**Supporter:** Center for Health Technology and Innovation

### 12:30-1:15 p.m. EST

**A Focus on Very High-Risk Patients in the Acute Setting: Understanding Vulnerable Plaque and Prioritizing LDL-C**

In this presentation, Dr. Michael Blaha will discuss the importance of cholesterol management in very high-risk ACSVD patients in the acute setting and focus on plaque vulnerability and the role of LDL-C. Don’t miss this informative presentation and discussion of a treatment option.

**Supporter:** Amgen Cardiovascular

### 1:45-2:15 p.m. EST

**Clinical Insights in CAD and/or PAD: Reducing the Risk of Major Cardiovascular Events**

Patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) are at risk for major cardiovascular events, including cardiovascular death, myocardial infarction and stroke. This lecture will discuss an approach to reducing the risk of these events.

**Supporter:** Janssen Pharmaceuticals, Inc.

**Opportunities to Improve Health Outcomes in ASCVD: A Focus on Population Health and a Call to Action for Health Equity**

This disease state education program will focus on strategies to improve health outcomes in atherosclerotic cardiovascular disease (ASCVD). Key discussion topics will include an update on the prevalence and disease burden of ASCVD, exploring/differentiating population health approaches to optimize the primary and secondary prevention of ASCVD and a call to action to promote health equity and improve outcomes for ASCVD in the United States.

**Supporter:** Novartis Pharmaceuticals Corporation - Medical Affairs

### 3-4:30 p.m. EST

**NHLBI Company Showcase**

The American Heart Association (AHA) and the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) are convening at this year’s Scientific Sessions to host a live virtual pitch exhibition featuring six NHLBI-funded companies. Attendees will have the opportunity to learn about the latest innovative cardiovascular technologies from each company. These companies are part of a larger portfolio of companies that are supported by the NHLBI Small Business Program, and will receive funding, coaching and partnering support as part of this program. After the session, attendees will be able to network and engage with each company.

**Supporter:** Bristol Myers Squibb

---

These events are not part of the official Scientific Sessions 2021 as planned by the AHA Committee on Scientific Sessions Program.
Sunday, Nov. 14

9:30-10:15 a.m. EST

Implementing GDMT in Worsening Heart Failure Patients – Easy or Challenging? A Debate
This session will explore the complexities of implementing GDMT in patients with worsening heart failure. Your peers will identify key clinical challenges and best practices, as well as discuss specific patient types that pose greater challenges to GDMT implementation. This will be followed by a spirited, collegial debate about the “ease” of implementing GDMT. A brief review of the new universal definition of heart failure and its new classification will set the stage for this lively debate.

Supporter: Cytokinetics, Inc.

Add on Efficacy. Oral, Nonstatin Therapies for Lowering LDL-C
- Atherosclerotic cardiovascular disease and lipid management
- Unique mechanism of action for two treatment options
- Efficacy data for two treatment options
- Safety data for two treatment options
- Overview of the ongoing Outcomes trial

Supporter: Esperion Therapeutics, Inc.

11-11:45 a.m. EST

Clinical Insights in NVAF: Reducing the Risk of Stroke and Systemic Embolism
Patients with nonvalvular atrial fibrillation (NVAF) are at risk of stroke. This lecture will present options for reducing the risk of stroke in patients with NVAF and in patients with NVAF and obesity.

Supporter: Janssen Pharmaceuticals, Inc.

Double Trouble: AF & HF
Following a deteriorating spiral of disease progression, heart failure (HF) and atrial fibrillation (AF) can present a significant public health challenge. Early rhythm control in AF can improve clinical outcomes, including among AF patients with HF. Unfortunately, siloed care leaves many patients undiagnosed and untreated. Join Drs. Jagmeet Singh and Javed Butler as they discuss exciting new data on the management of these patients and how to bridge the clinical divide to improve patient care.

Supporter: Sanofi

Cholesterol Efflux Hypothesis: Rethinking Good Cholesterol
CSL Behring is pleased to support the 2021 AHA Scientific Sessions Learning Studio, entitled 'Cholesterol Efflux Hypothesis: Rethinking Good Cholesterol'. Chair Prof. Roxana Mehran will facilitate presentations and discussion with Prof. Gilles Montalescot and Prof. Dominick Angiolillo. The experts will discuss the risk of early recurrent CV events and the unmet need in the 90-day high-risk period following a heart attack, along with the relationship between cholesterol efflux capacity and CV outcomes.

Supporter: CSL Behring

12:15-1 p.m. EST

The Journey to Diagnosis: Recognizing the Signs and Symptoms of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin amyloid cardiomyopathy (or ATTR-CM) is an underrecognized and underdiagnosed disease that leads to heart failure. This presentation from a leading expert will provide an overview of ATTR-CM and highlight how to recognize the signs and symptoms that raise suspicion of ATTR-CM, while introducing approaches to achieve an appropriate diagnosis. The program will end with a review of the clinical data for a treatment option for ATTR-CM.

Supporter: Pfizer, Inc.

Diagnosing Aortic Stenosis in Women to Close the Treatment Gap
Despite medical advancements, gender disparities prevail regarding diagnosis and treatment for Valvular Heart Disease. With a focus on Aortic Stenosis, Dr. Pam Taub will use an evidence-based approach and patient examples to highlight the gender treatment gap. Dr. Taub will also cover the need for early detection in alignment with the latest ACC/AHA guidelines and share practical examples to help overcome barriers that
impede timely intervention for women. Learning Studio discussion also includes SMART Trial details.

**Supporter:** Medtronic

**Evolving the Chronic Heart Failure Treatment Paradigm in Cardiology**  
This program will use a case-based approach to review the clinical impact of recent developments in the treatment of chronic heart failure.  
**Supporter:** Novartis Pharmaceuticals Corporation

**3:30-4:15 p.m. EST**

**VASCEPA® (icosapent ethyl): Elevating the Standard of Care**
There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statin-based standard-of-care therapy in patients with elevated triglycerides. In this program, we will review data from a practice changing trial that provides a groundbreaking therapeutic option to elevate the current standard of care.  
**Supporter:** Amarin Pharma, Inc.

**Monday, Nov. 15**

**9:30-10:15 a.m. EST**

**How the Democratization of Fitness Can Improve Health Outcomes**
Planet Fitness CEO Chris Rondeau and the 17th Surgeon General of the United States Dr. Richard Carmona will discuss the benefits of physical activity for preventative health and for those who have undergone cardiovascular therapies. Mr. Rondeau, a pioneer of the low-cost/high value fitness offering, has led the expansion of Planet Fitness as one of the largest fitness brands in the world. Dr. Carmona, a leading advocate for health literacy, has worked to close the gap in health disparities.  
**Supporter:** Planet Fitness, Inc.

**12:30-1:15 p.m. EST**

**A Treatment Option for Patients With HFrEF Following a Worsening HF Event**
- Highlight the burden of HFH in patients with HFrEF  
- Review a treatment option for reducing the risk of HFH and CV death in patients with HFrEF  
**Supporter:** Merck & Co., Inc.

**Comprehensive & Expanding: Overview of MEDTRONIC’s SPYRAL-HTN Global Clinical Trial Program**
Attend this session if you want to:  
- Understand the latest clinical evidence from the SPYRAL-HTN OFF MED and SPYRAL-HTN ON MED  
- Learn more about the long-term durability and safety of renal denervation in a real-world patient population  
- Review the latest guidance from key US societies regarding renal denervation with the experts  
**Supporter:** Medtronic

---

Explore these AHA initiatives in the Virtual Exhibit Hall

- Research  
- Scientific Journals  
- Hands Only CPR  
- Quality Improvement (QORA)  
- Consumer Health  
- Lifelong Learning  
- Target Aortic Stenosis  
- Healthcare Business Solutions (ECC)
Virtual Event OnDemand Access
Registered Attendees Only
Nov. 13–Dec. 15, 2021

Registered attendees can access the cutting-edge basic, translational and clinical science virtually from Nov. 13–Dec. 15, 2021.

Sessions OnDemand Extended Access
Free for AHA Members

Scientific Sessions 2021 OnDemand Extended Access!
Access the latest cardiovascular science anytime, anywhere, and earn CE! Stay current digitally with educational content to match your interests. Learn whenever, wherever—virtually!

If you were unable to attend AHA’s Scientific Sessions 2021, or you just want to catch-up on presentations that you might have missed, you can continue to experience the meetings virtually through OnDemand Extended Access.

OnDemand Extended Access is available for FREE to all paid levels of AHA Members, and available for purchase to those who choose to remain non-Members.

For more information, please click here.
Two AHA specialties—Resuscitation Science Symposium (ReSS) and Quality of Care and Outcomes Research (QCOR) Scientific Sessions—are being held in conjunction with Scientific Sessions 2021.

#RESS21

Benjamin S. Abella, MD, MPhil, FAHA
ReSS Program Committee Chair

Michael W. Donnino, MD
ReSS Program Committee Vice Chair

#QCOR21

Umesh Khot, MD
Chair, QCOR Program Committee

Emily O’Brien, PhD
Vice Chair, QCOR Program Committee

#ReSS21 takes place Nov. 12-14. ReSS programming will lead clinicians and researchers in discussions of recent advances related to treating cardiopulmonary arrest and life-threatening traumatic injury. With a better understanding of the shared pathophysiology between cardiac arrest and traumatic injury at multiple levels of biological organization, ReSS can provide a unique opportunity for transdisciplinary interactions that rapidly translate advances in the resuscitation field from fundamental to translational to clinical to population science.

ReSS programming includes:
- Updates in Post-Arrest Targeted Temperature Management (TTM)
- New Directions in Intra-Arrest Management
- Survivorship: Current Needs and Knowledge Gaps
- The Year in Review and ILCOR Update
- Special Circumstances in Resuscitation
- Late Breaking Resuscitation Science
- Oral Abstract Presentations, including Best of the Best Oral Abstracts
- Moderated Digital Posters and ePoster Presentations

Sessions for the Quality of Care and Outcomes Research Meeting (QCOR) Conference 2021 will be presented Nov. 15.

Participants in the Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2021 Scientific Sessions play a major role in efforts to improve the quality of cardiovascular medical care and patient outcomes. It is the only major international meeting focused on cardiovascular issues in which clinical researchers interact in a meaningful way with policy makers and quality outcomes experts. The confluence of these players is critical in today’s changing healthcare environment, in which quality and cost issues can no longer be divorced from clinical care or the patient experience.

Highlights of QCOR at Sessions include:
- Early Career Investigator Award
- The State of the Art in mHealth for Cardiovascular Disease (AHA SFRN for Health IT)
- Circ:CQO Journal Editorial Board
- Global Cardiovascular Outcomes
- Abstract Oral Sessions
- ePosters and Moderated Digital Posters
- QCOR Awards 2021 and Moderated Networking Session

Umesh Khot, MD
Chair, QCOR Program Committee

Emily O’Brien, PhD
Vice Chair, QCOR Program Committee
Symposia Schedule

Saturday, Nov. 13

Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science and Strategies for Early Diagnosis and Tailored Treatment
6:30-7:30 a.m. EST
COMMUNITIES: Cardiometabolic Health and Diabetes (Population) Primary, Acute Coronary Syndromes (Clinical) Secondary
SPONSOR: In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity is supported through an educational grant from Bristol Myers Squibb. This activity has been developed in partnership with the Hypertrophic Cardiomyopathy Association.
Learn more

Managing the Heart Failure Patient With Reduced Ejection Fraction: New Perspectives and Emerging Evidence
5:30-7 p.m. EST
COMMUNITIES: Heart Failure and Cardiomyopathies (Primary); Pulmonary Hypertension and Critical Care (Secondary)
SPONSOR: This activity is supported by an independent educational grant from Cytokinetics Incorporated
Learn more

GLP-1 RAs in Type 2 Diabetes: Clinical and Practical Considerations in Cardiology
5:30-6:30 p.m. EST
COMMUNITIES: Failure and Cardiomyopathies (Clinical) Primary; Cardiac Development, Structure and Function (Basic) Secondary; Imaging and Nuclear Medicine (Clinical) Tertiary
SPONSOR: Eli Lilly and Company
Learn more

Cases and Conversations™: Making the Most of Effective Antithrombotic Strategies in Patients with CAD and PAD
6:30-8 p.m. EST
COMMUNITIES: Vascular Disease and Thrombosis (Clinical); Arteriosclerosis, Thrombosis, Vascular Biology (Basic); Prevention Health & Wellness (Population)
SPONSOR: Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
Learn more

Antiplatelet Therapy in Patients With Coronary Artery Disease and Acute Ischemic Stroke/Transient Ischemic Attack: A Personalized Approach
7:30-9 p.m. EST
COMMUNITIES: Interventional Treatments (Primary); Acute Coronary Syndromes (Secondary); Stroke and Neuroscience (Tertiary)
SPONSOR: This activity is supported by an educational grant from AstraZeneca Pharmaceuticals
Learn more

These events are not part of the official Scientific Sessions 2021 as planned by the AHA Committee on Scientific Sessions Program.
Sunday, Nov. 14

Screening and Management of Chronic and Diabetic Kidney Disease: How Does Your Approach Compare With the Experts?
6-7:30 a.m. EST
COMMUNITIES: Cardiometabolic Health and Diabetes; Interventional Treatments; Metabolism and Physiology
SPONSOR: This activity has been supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Learn More

Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?
5-6 p.m. EST
COMMUNITIES: Cardio-Oncology (Clinical) Primary; Heart Failure and Cardiomyopathies (Clinical) Secondary; Electrophysiology and Arrhythmias (Clinical) Tertiary
SPONSOR: In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity is supported through an educational grant from Bristol Myers Squibb.
Learn more

Clinical Run Down: 3 Hot Topic Sessions on ASCVD Risk Reduction
7:30-9 p.m. EST
COMMUNITIES: Acute Coronary Syndromes (Clinical), Arteriosclerosis, Thrombosis, Vascular Biology (Basic), Cardiometabolic Health and Diabetes (Population)
SPONSOR: Medintelligence
Learn more

Hidden in Plain Sight: ATTR CM in Overlooked Patient Populations
7:30-9 p.m. EST
COMMUNITIES: Primary: Heart Failure and Cardiomyopathies (Clinical); Secondary: Genetics and Genomics (Basic); Third: Special Populations (Population)
SPONSOR: Ionis Pharmaceuticals
Learn more

Monday, Nov. 15

Achieving Lipid Goals: Expert Cardiologist Perspectives on Strategies Beyond Statin Therapy
5-6:30 p.m. EST
COMMUNITY: Vascular Disease and Thrombosis (Clinical)
SPONSOR: MedscapeLIVE! on behalf of Esperion Therapeutics
Learn more

Improving Management of AF: Translating Advances in Early Rhythm Control Strategies Into Everyday Practice
5-6:30 p.m. EST
COMMUNITY: Electrophysiology and Arrhythmias (Clinical)
SPONSOR: MedscapeLIVE! on behalf of Sanofi
Learn more

These events are not part of the official Scientific Sessions 2021 as planned by the AHA Committee on Scientific Sessions Program.
Center for Health Technology & Innovation

Your opportunity to explore the leading edge of innovation and collaboration in the cardiovascular and digital health space. Key thought leaders will discuss solutions that span the cardiovascular health spectrum, with a goal of leveraging health tech for longer, healthier lives.

Saturday, Nov. 13

9:30 a.m. EST
Advanced Digital Therapeutics for Chronic Conditions

FEATURED EVENT
11 a.m. EST
Potential Impact of Virtual Longitudinal Studies

1 p.m. EST
Digital Cardiac Rehab

3 p.m. EST
Self-Measured Blood Pressure Platforms and Devices

Sunday, Nov. 14

9 a.m. EST
Health Equity and Cardiovascular Disease

11 a.m. EST
Doctors With Heart

12:30 p.m. EST
Innovation Showcase

3:15 p.m. EST
Mental Health and Cardiovascular Disease

Monday, Nov. 15

9 a.m. EST
AHA’s Digital Content Delivery System

11 a.m. EST
Cloud-Based AI and Smart Monitoring

1 p.m. EST
SFRN for Health Tech Roundtable
Frontiers in Science Summits

Frontiers in Science brings together early, mid- and senior investigators to debate the latest breakthroughs and pre-publication discoveries in the areas of arrhythmia research, thrombosis and vascular disease.

Arteriosclerosis, Thrombosis, Vascular Biology

Frontiers in Thrombosis
- Genetic and Molecular Mechanisms of Cardiovascular Calcification

Vascular Disease and Thrombosis

Frontiers in Vascular Disease
- COVID-19 and Coagulopathy: Trailblazing Pathways to Prevention and Treatment
- Everything Old Is New Again: Emerging Therapies for Thrombotic Disorders

Electrophysiology and Arrhythmias

Arrhythmia Research Summit
- Novel Therapies Targeting Arrhythmogenesis: Bringing the Bench to the Bedside
- Clinical Applications of Multi-Omic Data
- Translating Basic to Clinical Research in Atrial Fibrillation
- Translational Research Targeting Ventricular Arrhythmias and Sudden Death
- Arrhythmia Applications of Digital Health and Precision Medicine
- Special Topics and Innovations in Arrhythmia Management

Refer to the Online Program Planner for more details.

Available OnDemand
8 a.m. EST, Saturday, Nov. 13
Scientific Sessions is offering several hours of Early Career programming, including topics such as surviving the era of COVID, career strategies, making the move to your own practice and more.

### Saturday, Nov. 13

- **2:30 p.m. EST**
  - Strategies for Career Success by Highly Effective Scientists

- **3 p.m. EST**
  - 3CPR Speed Mentoring

- **3:30 p.m. EST**
  - Surviving in the Early Career: Transitions to Outside Academia

- **4:30 p.m. EST**
  - Successfully Navigating a COVIDilized Scientific World as an Early Stage Investigator
  - Interview With Nursing Legends in Cardiovascular Science

### Sunday, Nov. 14

- **8 a.m. EST**
  - Leveling the Playing Field: Mentorship and Sponsorship to Promote Early Careers in Pediatric Cardiology

- **9:30 a.m. EST**
  - Tool Kit for Early Career Vascular Specialists

### Monday, Nov. 15

- **8 a.m. EST**
  - Early Career Cardiac Imaging Boot Camp

- **11 a.m. EST**
  - Customizing Your Career: An Open Discussion With Distinguished Panelists
  - Top Early Career Tips in Cardio-Oncology: Paving the Way
Early Career Clinical Case Competition

AHA Early Career Clinical Case Competition. Fellows in training or clinicians within 5 years of completing post-graduate education submitted their case report to compete for the Gold, Silver and Bronze Award at AHA Scientific Sessions 2021. For more detail, view the online program planner.

Clinical Case Competition Gold Award Cases

This session highlights the clinical case abstracts having been recognized as the AHA Early Career Clinical Case Competition Gold awardees. These high quality and applicable case reports provide an important learning opportunity for all clinicians.

292 - Radiation-Induced Accelerated Multi-Valve Disease in a Patient With Subaortic Membrane

293 - Unexplained Recurrent St-Elevation Myocardial Infarction Complicated by Diffuse Alveolar Hemorrhage in Undiagnosed Granulomatosis With Polyangiitis

294 - Cardiac Sarcoidosis Mimicking Arrhythmogenic Right Ventricular Cardiomyopathy Presenting With Syncope

295 - Recurrent Atrial Myxomas as a Presenting Feature of Carney Complex

296 - Complications of a Severe Case of Multisystem Inflammatory Syndrome in Children

297 - Multidisciplinary-Team Management of a Severely Ill Pregnant COVID-19 Patient With a Newly Diagnosed Severe Mitral Stenosis

Clinical Case Competition Silver Award Cases

This session highlights the clinical case abstracts having been recognized as the AHA Early Career Clinical Case Competition Silver awardees. Attend this session and challenge your diagnostic skill.

P2981 - Cisplatin Induced Coronary Artery Atherosclerosis Leading to St-Elevation Myocardial Infarction: A Case Report

P2982 - Rapidly Lethal Dilated Cardiomyopathy Secondary to Generalized Arterial Calcification of Infancy
P2983 - Novel Association of Left Ventricular Outflow Tract Obstructions With Chromosome 5p Deletions

P2984 - Cabozantinib Induced Cardiomyopathy; Second Reported Case of a Rare Adverse Effect

P2985 - Primary Cardiac Sarcoma In Elderly Patient And Need For High Index Of Suspicion

P2986 - Hunting For Clot: Strokes In Patients With Cardiac Amyloid

P2987 - Amiodarone for Atrial Fibrillation in the Setting of Cardiogenic Shock and Thyroid Storm

P2988 - A Pair of Diaphragm-Crossed Organs: A Pancreatico-Pericardial Fistula

P2989 - Primary Hyperaldosteronism and Resistant Hypertension in Pregnancy

P2991 - Reversible Golimumab Induced Cardiomyopathy - First Reported Case Report

P2992 - End Stage Mitochondrial Cardiomyopathy and Heart Transplantation Due to Pathogenic Biallelic C1QBP Variants

P2993 - Report of an Adult Living With Undiagnosed Total Anomalous Pulmonary Venous Return

P2994 - Nintedanib and Cardiomyopathy: A Vascular Failure?

Clinical Case Competition Bronze Award

This session highlights the clinical case abstracts having been recognized as the AHA Early Career Clinical Case Competition Bronze awardees. Case reports are inclusive of several cardiac and stroke specialty areas.

P2995 - A Rare Case of COVID-19 Induced Thrombus-in-Transit Going Through a PFO in a Pregnant Patient

P2996 - The Effect of Rhabdomyomas on Underlying Cardiomyopathy: A Case Report

P2997 - Acute Ventricular Septal Rupture Management by the Cardiac Intensivist

P2998 - Ocrelizumab Induced Kounis Syndrome
P2999 - COVID-19 Vaccine Associated Acute Myocarditis

P3000 - Pacemaker for First Degree AV Block Without Bradycardia: Pseudo-Pacemaker Syndrome

P3002 - Provoked PFO Shunt and Posterior Circulation Stroke: An Underrecognized Association

P3003 - Outside The Box But All Squeezed In: A 23-year-old Man With Progressive Dyspnea After Overseas Travel

P3004 - Hyperhomocysteinemia Associated St Elevation Myocardial Infarction in a Young Male

P3005 - Primary Intimal Sarcoma of the Pulmonary Artery in a Patient With Laboratory Confirmed Heterozygous Factor V Leiden Mutation: A Case Report

P3006 - Simultaneous Mitral Valve Replacement, Aortic Valve Replacement, Tricuspid Valve Repair, Left Atrial Appendage Ligation, Maze Procedure And CABG in a 57-Year-Old Female With History of TAVR and Severe Mitral Annular Calcification

P3007 - Tropheryma Whipplei Endocarditis: A Diagnosis in Hindsight

P3008 - Not Just Another Knick In The Wall: An Unusual Case Of Multiple Arterial Aneurysms

---

**Early Career Programming On-Demand**

- Scientific Journeys of ATVB Young Investigators: Cutting-Edge Science Driving Cardiovascular Discovery
- Tips and Tricks for a Successful Transition to Practice
- Being a Successful Mentee and Mentor: Transitions and Evolution Across the Career Life Course
- Single-Cell Transcriptomics: a Flipped Classroom Experience in Data Analysis
- Single-Cell RNA Sequencing: Introduction to Analysis
- Advanced Heart Failure Feud: VADS Vs > Heart Transplant
- Meet the Experts: Leaders of NHLBI and NINDS-Funded Cohorts
- Nursing Science to Promote the Cardiovascular Health of Marginalized Populations Across the Lifespan
- Turning a Tornado Into a Pirouette: Surviving in the Era of COVID
- Beyond Adjusting for Race and Ethnicity: Doing Disparities Research Well
- Jumpstarting Your Career in Cardiovascular Surgery and Anesthesia
- Cardiovascular Science and Clinical Career Development During COVID-19
Networking is easier than ever on the #AHA21 virtual platform. Networking can occur in multiple areas of the site. The Networking area can be accessed either from the Top-Level Navigational bar and/or from the “Connect with Colleagues” tile on the Home Page.

You will be able to view other attendees and exhibitors at Scientific Sessions as well as sign up for live showcases that have been scheduled by exhibitors. When viewing attendees and exhibitors, you will be able to chat or schedule meetings.

Other areas of the Networking area include: Live Q&A and chat feature in conference app, Meet the Trialist, Roundtable events and social media.

Networking capabilities include:
• Meet attendees
• Schedule a meeting
• Host a new meeting
• Join a meeting
• Accept and decline meetings
• Video meetings
• Direct chats
• And more!
Discover the latest
Science & Technology
in the Virtual Exhibit Hall

Listings current as of Nov. 3, 2021

A-C

**Acceleron Pharma Inc.**
128 Sidney St.
Cambridge, MA 02139
e medinfo@xlrn.com
w www.acceleronpharma.com

**AHA Get With The Guidelines**
7272 Greenville Ave.
Dallas, TX 75321
w www.heart.org/resuscitation
Get With The Guidelines®- Resuscitation is the American Heart Association’s collaborative quality improvement program demonstrated to improve adherence to evidence-based care of patients who experience an in-hospital resuscitation event or received post cardiac arrest care following an in-hospital or out-of-hospital event. The program facilitates the efficient capture, analysis and reporting of data that empowers and supports the implementation of current guidelines, creation and dissemination of new knowledge, and development of next generation, evidence-based practice in resuscitation science. Hospitals can track data for Cardiopulmonary Arrest (CPA), Medical Emergency Team (MET), Post-Cardiac Arrest Care (PCAC) and Acute Respiratory Compromise (ARC). The web-based Patient Management Tool™ (powered by IQVIA) provides decision support, robust registry, real-time benchmarking capabilities and other performance improvement methodologies toward the goal of enhancing patient outcomes and saving lives. The primary goal of Get With The Guidelines-Resuscitation is to save more lives by preventing in-hospital cardiac arrest and optimizing outcomes through benchmarking, quality improvement, knowledge translation, and research.

**AHA Hands Only CPR**
7272 Greenville Ave.
Dallas, TX 75321
w www.heart.org/handsonlycpr
Someone — maybe a friend or even a family member — has cardiac arrest right in front of you. Their heart has stopped beating. They need help. What do you do? A survey shows that only half of Americans would perform lifesaving CPR. That’s because the other half don’t know what to do, fear legal ramifications or hurting the victim, and think someone else will come to the rescue. We get it. But the benefits of performing CPR far outweigh the risk and can double or triple the chance of survival. So don’t wait for someone else to step up. Learn and do CPR. You might even save someone you love.

**AHA Healthcare Business Solutions (ECC)**
7272 Greenville Ave.
Dallas, TX 75321
w www.heart.org/cpr
The American Heart Association’s CPR & ECC inspires the world to save lives and envisions a world where no one dies from cardiac arrest. The AHA is the leader in resuscitation science, education, and training, and publisher of the official Guidelines for CPR and ECC. Millions of healthcare providers and others trust the AHA for their lifesaving training, and 100% of the AHA’s profits go back into supporting its lifesaving mission.
**AHA International**
7272 Greenville Ave.
Dallas, TX 75321
w www.heart.org/en/professional/qi/improvement/international

The international department of the American Heart Association expands our efforts to build healthier lives, free of heart disease and stroke around the world. With staff in seven countries and programs in more than 100, we work to build powerful partnerships with government, health care and cardiovascular organizations that are committed to advancing heart and brain science and health, improving care for patients, supporting caregivers and training more people in first aid and CPR.

**AHA Lifelong Learning**
7272 Greenville Ave.
Dallas, TX 75321
w www.learn.heart.org

The premier provider in quality science, evidence based continuing education for healthcare professionals.

**AHA Quality Improvement (QORA)**
7272 Greenville Ave.
Dallas, TX 75321
w www.heart.org/quality

When medical professionals apply the most up-to-date evidence-based treatment guidelines, patient outcomes improve. That’s the simple truth behind the drive for continuous quality improvement. Our comprehensive suite of programs can help you advance farther and faster in the quest for ever-better care.

**AHA Research**
7272 Greenville Ave.
Dallas, TX 75321
w www.professional.heart.org/en/research-programs

Research Funding; Online Course Discounts; Career Enhancement. The AHA has invested $4.9 billion in research since 1949 and launched the careers of many of this country’s most prominent cardiovascular and brain scientists, including 14 Nobel prize winners.

Our bold research vision emphasizes collaborative & team research, accelerates discovery, and drives groundbreaking research outcomes.

Want funding for your research? How can the AHA enhance your career? Chat with us here or schedule a 1:1 appointment!

**AHA Scientific Journals**
7272 Greenville Ave.
Dallas, TX 75321
w www.AHAjournals.org

As the world leader in cardiovascular and cerebrovascular research, the AHA Scientific Journals aren’t simply publishing findings—They’re publishing research with immediate impact and enduring foundational value. The AHA Scientific Journals are your trusted source for investigations that innovate noninvasive and surgical techniques and procedures in the field and therapies for improved patient care.

**AHA Target: Aortic Stenosis**
7272 Greenville Ave.
Dallas, TX 75321
w www.heart.org/TargetAS

Aortic stenosis is one of the most common and serious heart valve disease problems with severe aortic stenosis affecting more than 1.7 million Americans over age 65. However, many patients are unaware or undiagnosed, which is why the American Heart Association continues to drive efforts for timely diagnosis, appropriate treatment, improved quality of care initiatives and comprehensive patient and caregiver resources to combat the disease.

To tackle the problem, the American Heart Association has launched the Target: Aortic Stenosis initiative, a program aimed to develop optimal standards of care via a learning collaborative comprised of experts and volunteers from pilot hospital locations around the nation. To learn more, visit: www.heart.org/TargetAS

Edwards Lifesciences is the national sponsor of Target: Aortic Stenosis

**Alexion, AstraZeneca Rare Disease**
121 Seaport Blvd.
Boston, MA 02210
w www.alexion.com

Intended for US audiences only Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Gamification is sponsored by the event organizer and is not sponsored by or related to Alexion.

**AHA/ASA Patient Health**
7272 Greenville Ave.
Dallas, TX 75321
w www.heart.org

The patient health team of the American Heart Association/American Stroke Association work collaboratively to bring the mission of the AHA/ASA to life. We envision a world in which all people living with or at risk for cardiovascular conditions have the care and support they need to survive and thrive. Our work empowers patients and consumers so that they may engage in their health journey and achieve sustainable health improvement. We are champions for all patients and drivers in creating a world of longer, healthier lives.
**Amarin Pharma, Inc.**

440 Route 22, Suite 300
Bridgewater, NJ 08807

p 908-326-1310
e andrew.watson@amarincorp.com
w www.amarincorp.com

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa, visit www.vascepa.com. For more information, visit www.amarincorp.com.

**American College of Cardiology**

Heart House 2400 N St. NW
Washington, DC 20037
e membercare@acc.org
w www.ACC.org/ACCCentralAHA

Over its 70-year history, the American College of Cardiology (ACC) has grown into the global leader in transforming cardiovascular care and improving heart health. With more than 54,000 members from over 140 countries, ACC has been instrumental in increasing our knowledge of CV diseases, establishing best practices, preventing and treating heart disease, and improving patient care and outcomes around the world. The progress, advances, leadership, and determination to defeat CV diseases are why ACC has earned the reputation of being OutFront on everything cardiovascular-related. OutFront reflects ACC’s vision: a world where innovation and knowledge optimize cardiovascular care and outcomes.

**Amgen**

One Amgen Center Drive
Thousand Oaks, CA 91320
p 805-447-1000
e papark@amgen.com
w www.tenetfl.com/neuro

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

**Amryt Pharma**

245 First St., 18th Floor
Cambridge, MA 02142
w www.amrytpharma.com

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a growing commercial business and a significant development pipeline. A core belief at Amryt Pharma is that we operate on a foundation of responsibility, integrity and ethical practice. We aim to forge partnerships and collaborations that work for all. By listening to our stakeholders we create a clear path for our transformative medicines to reach those that need them.

**AstraZeneca**

Horizon Place 600 Capability Green
Lu1 3LU United Kingdom
p 800-236-9933
e laura.wright@astraZeneca.com
w www.astrazeneca-us.com

AstraZeneca is a global biopharmaceutical company that sets the standard in healthcare by turning science into innovative medicines. Its medicines empower patients around the world by putting science into practice. The company’s portfolio includes treatments for a range of serious diseases, including heart disease, cancer, and respiratory disorders. AstraZeneca’s core values ofinnovation, integrity, and respect shape the way the company operates.

**Bayer**

100 Bayer Blvd.
Whippany, NJ 07981
e athena.helmer@bayer.com
w www.pharma.bayer.com

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing aging population. Bayer is committed to the principles of sustaining development, and the Bayer brand stands for trust, reliability, and quality throughout the world.

This information has been reviewed according to the US law and is consistent with US Prescribing Information and is intended for HCPs only. Prescribing Information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the Prescribing Information and/or the Summary of Product Characteristics (SPC).

**BD**

321 South Taylor Ave. Suite 200
Louisville, CO 80027
e benjamin.walters@bd.com
w www.go.bd.com/Stat-Launch-Emotional.html#content

BD is a global medical technology company that benefits countless lives worldwide. The ARCTIC SUN™ Temperature Management System provides noninvasive core targeted temperature management with precision in adult and pediatric patients. The system translates sophisticated science into an intuitive interface, managing the therapy so you can manage the patient.
Boehringer Ingelheim/Lilly Commercial
900 Ridgebury Road
Ridgefield, CO 06877
p 203-798-5547
e rebecca.madrid@boehringer-ingelheim.com
w us.boehringer-ingelheim.com
Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA welcome you to AHA 2021. Visit us.boehringer-ingelheim.com or www.lilly.com. Our CVMET Alliance also welcomes you to visit pro.boehringer-ingelheim.com/us/products/jardiance/

Boehringer Ingelheim/Lilly Medical
900 Ridgebury Road
Ridgefield, CO 06877
p 203-798-5547
e rebecca.madrid@boehringer-ingelheim.com
w us.boehringer-ingelheim.com

BridgeBio, Inc.
101 Montgomery St.
Suite 2000
San Francisco, CA 94104
w www.bridgebio.com
BridgeBio is a team of experienced drug discoverers, developers, and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.

Bristol Myers Squibb
777 Scudders Mill Road
Plainsboro, NJ 08536
p 407-616-8529
e missy.lawson@bms.com
w www.bms.com
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

Bristol Myers Squibb / Pfizer
235 E. 42nd St.
New York, NY 10017
p 908-952-8410
e wendy.irvine@pfizer.com
w www.eliquis.com
The Bristol Myers Squibb and Pfizer alliance is a worldwide collaboration that brings together two leading companies focused on cardiovascular disease with a shared vision to reduce nonvalvular atrial fibrillation-related stroke and treat deep vein thrombosis/pulmonary embolism events. Explore the BMS and Pfizer virtual exhibit. Clicking the link will direct you to bmspifercongressresources.com that contains product information for U.S. health care providers only.

Cardiovascular Clinical Sciences Foundation
75 Kneeland St., Suite 702
Boston, MA 02111
p 617-423-7999
e Lrusch@ccsTrials.com
w www.ccstrials.com
Founded by cardiologists, Cardiovascular Clinical Science is a full-service CRO providing the highest level of clinical trial execution via integration of medical, site, and patient perspectives. CCS facilitates innovation and improves patient outcomes through cardiovascular therapeutics and diagnostics clinical trial expertise – anchored by accessible leadership, staff continuity, and global reach.

CL Laboratory, LLC
501 Callander Way
Abingdon, MD 21009
p 888-275-2605
e czheqing@cardio-lab.com
w www.cardio-lab.com
CL Laboratory LLC provides contract research services in cardiovascular efficacy studies using rodent models. CL laboratory was founded by experienced cardiac researchers from the Johns Hopkins Medical Institutions six years ago.
Cytokinetics
280 E. Grand Ave.
South San Francisco, CA 94080
p 650-624-3228
e lgschwind@cytokinetics.com

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases.

Edwards Lifesciences
One Edwards Way
Irvine, CA 92614
p 949-250-6739
e THVConferences@Edwards.com
w www.edwards.com

Big ideas with the power for change are the cornerstone on which Edwards Lifesciences was founded. So when we ask ourselves, is it possible? The answer must be yes. Because improving the quality of life for structural heart patients around the world has always been our mission.

Esperion Therapeutics
450 East St.
Doylestown, PA 18901
p 215-345-1515
e hpaige@esperion.com
w www.esperion.com/

Singularly focused on lipid management for everybody.

European Society of Cardiology (ESC)
e membership@escardio.org
w www.escardio.org

The European Society of Cardiology is the world’s largest organisation of healthcare professionals dedicated to fighting heart disease. Through our global network of 57 National Cardiac Societies and 48 Affiliated Cardiac Societies, we help more than 100,000 clinicians, scientists, nurses and allied professionals expand the boundaries of cardiovascular medicine. The ESC publishes 16 scientific journals, an array of textbooks and world-renowned ESC Clinical Practice Guidelines. It provides continuing medical education through online programmes, financial support through grants and hosts the summit of cardiovascular science each August – ESC Congress.

FDA Center for Tobacco Products
e CTPOutreach@fda.hhs.gov
w www.fda.gov/tobacco-products

Welcome to the U.S. Food and Drug Administration’s Center for Tobacco Products (CTP) exhibit booth. CTP regulates the manufacturing, marketing, and distribution of tobacco products. CTP’s mission is to make tobacco-related death and disease part of America’s past, not America’s future, and, by doing so, ensure a healthier life for every family.

FUJIFILM VisualSonics
3080 Yonge St.
Toronto, ON M4N 3N1 Canada
p 416-484-5000
e mandi.dasilva@fujifilm.com

FUJIFILM VisualSonics, Inc is the undisputed world leader in real-time, high-resolution preclinical imaging systems, providing modalities specifically designed for cardiovascular researchers. These cutting-edge technologies are utilized by researchers at the world’s most prestigious pharmaceutical and biotechnology companies and universities. This trusted and well-validated technology has been used in over 2000 peer-reviewed publications. The Vevo systems workflow and software are also available with 4D imaging, Strain analysis and automated LV functional assessments. VisualSonics platforms combine high-resolution, real-time in vivo imaging with ease-of-use and quantifiable results.

Great Wall International Congress of Cardiology
11 # Xizhimen S. Ave.
Beijing, 100044 China
e shangran@heartonline.cn
w www.gw-icc.com/

Inari Medical
9 Parker, Suite 100
Irvine, CA 92618
p 714-260-4422
e jennyh@inarimedical.com
w www.inarimedical.com

Inari Medical is pioneering therapeutic treatments for venous thromboembolism by developing thrombectomy products to extract large clot burden from big vessels without the need for thrombolytic drugs.
Intermountain Healthcare
5121 S. Cottonwood St.
Murray, UT 84107
p 801-507-4757
e judy.smith@imail.org
w www.intermountainhealthcare.org/services/heart-care/heart-institute

Intermountain Healthcare is a leader in providing evidence-based, best-practice cardiovascular care to patients throughout the nation.

Invitae
1400 16th St.
San Francisco, CA 94103
p 720-818-4350
e pamela.balsley@invitae.com
w www.invitae.com

Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Our goal is to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time and lower prices.

Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
p 760-268-4985
e AGlover@ionisph.com
w www.ionispharma.com

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. To learn more about Ionis’s cardiometabolic franchise, visit www.ionispharma.com.

J-L

JAMA Network
330 N. Wabash Ave.
Suite 39300
Chicago, IL 60611
p 312-464-4868
e Millette.jackson-bates@ama-assn.org
w www.jamanetwork.com

Janssen Pharmaceuticals, Inc.
1125 Trenton-Harbourton Road
Titusville, NJ 08560
p 512-305-3686
e llamarc1@its.jnj.com
w www.janssen.com

The Janssen Pharmaceutical Companies of Johnson & Johnson never stop working to create a future where disease is a thing of the past.

Kiniksa Pharmaceuticals
100 Hayden Ave.
Lexington, MA 02421
p 339-970-9451
e jmckenna@kiniksa.com
w www.kiniksa.com

Kiniksa Pharmaceuticals is a global biopharmaceutical company that finds and delivers novel treatments for patients with a significant unmet need. We focus on cultivating a highly skilled and passionate team determined to deliver the promise of transformative therapies to patients who need them most. We are focused on building a better future for patients by developing a portfolio of differentiated and transformational therapeutics for patients with serious and life-threatening diseases. In March of 2021, Kiniksa received FDA approval for Arcalyst® (rilonacept). Visit kiniksa.com for more information.

Kiniksa Pharmaceuticals Medical
100 Hayden Ave.
Lexington, MA 02421
e akachinsky@kiniksa.com

Know Diabetes By Heart
7272 Greenville Ave.
Dallas, TX 75231
w www.knowdiabetesbyheart.org/
The American Heart Association and the American Diabetes Association, along with industry leaders, have proudly launched the groundbreaking collaborative initiative Know Diabetes by Heart™ to reduce cardiovascular deaths, heart attacks and strokes in people living with type 2 diabetes. With support from founding sponsors, the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance and Novo Nordisk, and national sponsors Sanofi, Astra Zeneca, and Bayer the Know Diabetes by Heart™ initiative seeks to comprehensively combat the national public health impact of type 2 diabetes and cardiovascular disease by:

Raising awareness and understanding of the link between diabetes and cardiovascular disease. Positively empowering people to better manage their risk for cardiovascular disease, heart attacks and strokes. Supporting health care providers in educating their patients living with type 2 diabetes on cardiovascular risk and increasing their patients’ engagement in prevention of cardiovascular deaths, heart attacks and strokes.

M-O

Mayo Clinic
200 First St. SW
Gonda 6-472
Rochester, MN 55905
p 507-266-9457
e Atkinson.Teresa@mayo.edu

Mayo Clinic’s top-ranked team of cardiologists diagnoses and treats more than 100,000 adults and children each year, including those with complex or rare conditions.
Med Learning Group  
188 Tooker Ave.  
Springfield, NJ 07081  
p 908-418-1445  
e ajenkins@medlearninggroup.com  
w www.medlearninggroup.com  
Med Learning Group’s mission is to design educational activities for health care practitioners that increase competence, change behavior and optimize patient care. The focus of our education is to create innovative and interactive educational programs designed with scientific rigor, fair balance and evidence-based content. MLG emphasizes collaboration with academic and community-based hospitals, government agencies, medical associations, managed care organizations and other important stakeholders in the health care industry in order to provide pertinent educational activities that fill the educational gap for our relevant target audiences.

Medtronic  
710 Medtronic Parkway  
Minneapolis, MN 55432  
p 612-597-4793  
e kathryn.malen@medtronic.com  
Through innovation and collaboration, Medtronic improves the lives and health of millions of people each year. We offer the broadest range of innovative medical technology and services for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. Learn more about our technology, services and solutions at Medtronic.com.

Merck & Co., Inc.  
2000 Galloping Hill Road  
Kenilworth, NJ 07033  
p 908-740-6455  
e nadine.curtin@merck.com  
w www.merck.com  
For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions an

Natera  
201 Industrial Road  
San Carlos, CA 94070  
p 650-273-4468  
e kkim@natera.com  
w www.natera.com/organ-health  

National Heart, Lung, and Blood Institute (NHLBI)  
Building 31, Room 5A52 31  
Center Drive  
Bethesda, MD 20892  
p 571-373-5458  
e Isaiah.donaldson@icfnext.com  
w www.nhlbi.nih.gov  
The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training and education program to promote the prevention and treatment of cardiovascular diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.

NEJM Group  
860 Winter St.  
Waltham, MA 02451  
p 781-434-7414  
e lchase@nejm.org  
w www.nejmgroup.org  
NEJM Group products include the New England Journal of Medicine, NEJM Journal Watch, NEJM Knowledge+, NEJM Catalyst, NEJM Resident 360, NEJM Healer and NEJM. NEJM Group is a division of the Massachusetts Medical Society. Visit nejmgroup.org.

Northwestern Medicine  
251 E. Superior  
Chicago, IL 60611  
p 312-926-8895  
e bgarren@nm.org  
w www.heart.nm.org/  
Northwestern Medicine Bluhm Cardiovascular Institute – a health care destination for patients requiring highly specialized cardiovascular care. For the fifth consecutive year, U.S. News & World Report ranked our program top 10 in the nation.

Novartis Pharmaceuticals Corporation  
One Health Plaza  
PO #3002431634  
East Hanover, NJ 07936  
p 862-308-9826  
e marianne.santorelli@novartis.com  
w www.novartis.com  
Novartis is reimagining medicine to improve and extend people’s lives. We use innovative science and digital technologies to create transformative treatments. Novartis products reach more than 750 million people globally, and we are finding innovative ways to expand access to our medicines. About 105,000 people of more than 140 nationalities work at Novartis.

Novartis Pharmaceuticals Corporation – Medical Information  
One Health Plaza PO #3002431634  
East Hanover, NJ 07936  
p 862-308-9826  
e marianne.santorelli@novartis.com  
w www.novartis.com  
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally, and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.  
Find out more at www.novartis.com.  
medinfo.novartispharmaceuticals.com/EMedContactUs
Novo Nordisk Inc
Accounts Payable - LLCU/RSER 800 Scudders Mill Road
Plainsboro, NJ 08536
p 609-786-8321
e JXHM@novonordisk.com
w www.novonordisk-us.com
For more than 90 years, Novo Nordisk, a global leader in diabetes care, has been discovering and developing innovative medicines to help people with chronic diseases lead longer, healthier lives.

Novo Nordisk Medical
800 Scudders Mill Road
Plainsboro, NJ 08536
p 609-786-4124
e mzrd@novonordisk.com
w www.novonordisk.com/
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. With a strong, historical base in the treatment of diabetes, we now aim to also help patients within the cardiovascular field with both medicines from the treatment of type 2 diabetes but also new potential drugs in preventive cardiology and heart failure. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, please visit our websites and social media platforms below.

Omron
1925 W. Field Court
Lake Forest, IL 60045
p 858-254-6421
e jim.li@omron.com
w www.omronhealthcare.com
As the global leader in blood pressure monitoring, Omron® Healthcare offers a range of monitors to serve every one of the 103 million hypertensive American adults and those who want greater insights into their heart health.

Oxford University Press
2001 Evans Road
Cary, NC 27513
p 919-677-0977
e gab.exhibitions.us@oup.com
w bit.ly/AHA-2021
Oxford University Press is a department of the University of Oxford. It is our mission to further the University’s objective of excellence in research, scholarship, and education by publishing worldwide. Explore the top cited articles from the ESC Journals published by OUP. All articles are free to read.

Pfizer
235 E. 42nd St.
New York, NY 10017
p 215-882-4266
e deborah.j.hummel@pfizer.com
PF Pfizer Medical Affairs – Rare Cardiology
p 859-512-6560
e ashley.simmons2@pfizer.com
w www.pfi.sr/4tf

PhaseBio Introduces REVERSE-IT
One Great Valley Parkway, Suite 30
Malvern, PA 19355
p 610-981-6500
e kaye.kugler@phasebio.com
w www.phasebio.com
PhaseBio introduces REVERSE-IT (reverse-it-trial.com/)(Rapid and SustainEd ReVERSal of TicagrElor—Intervention Trial). In a virtual Late-Breaking Science session at the American Heart Association (AHA) Scientific Sessions 2021 on Monday, November 15, 2021, PhaseBio will present interim findings from REVERSE-IT, the pivotal Phase 3 trial designed to study reversal of the antiplatelet effects of ticagrelor with bentracimab in patients who present with uncontrolled major or life-threatening bleeding or who require surgery or an invasive procedure (NCT04286438). For more information on REVERSE-IT, please visit clinicaltrials.gov/ct2/show/NCT04286438. PhaseBio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for cardiovascular and cardiopulmonary diseases. PhaseBio is located in Malvern, PA, and San Diego, CA.

Quest Diagnostics, Inc.
500 Plaza Drive
Secaucus, NJ 07094
p 513-370-0541
e skoehler@adex-intl.com
w www.Questdiagnostics.com
Quest Diagnostics Cardiometabolic Center of Excellence is committed to empowering people to take action to improve health outcomes. Our menu of adv. CVD tests and Dx insights reveal new avenues to identify CVD risk, beyond cholesterol testing alone.
Regeneron Pharmaceuticals, Inc.
Sleepy Hollow Campus Office
3-3C403
p 914-847-8287
e jennifer.harrison@regeneron.com
w www.regeneron.com
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients across different therapeutic areas. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. For more information, please visit www.Regeneron.com or follow @Regeneron on Twitter.

For information regarding EVKEEZA® (evinacumab-dgnb) please copy and paste this URL into your web browser:

SCIRENT Clinical Research and Science
Amrumer Str. 16, 13353 Berlin, Germany
e goran.ebersold@scirent.com
w www.scirent.com
SCIRENT was founded as a cardiovascular CRO in 2012 with the vision to help clients develop innovative therapies and devices for Patients with cardiovascular diseases. Our team of experienced clinical and regulatory professionals shares your enthusiasm for developing effective therapies for CVD. We have developed strong relationships with research sites in Europe, META, and North America and our clients benefit from: 01 Scientific expertise combined with operational excellence from early phase to pivotal studies; 02 Regulatory expertise in numerous regions resulting in faster start-up time; 03 Patient access across numerous indications: HF, AF, CM, PAH, Atherosclerosis & CAD, Acute Ischemic Stroke, lipid disorders, aortic stenosis etc.

Tollos, Inc.
8 Easter Court, Suite J Owings Mills, MD 21117
e bschmidt@tollos.com
w www.tollos.com/vector
Created by physicians for physicians, Tollos is proud to introduce the VECTOR Lead Apron Suspension System. VECTOR transfers the weight of your lead apron away from your body. Work in comfort, with less stress and fatigue – and without any extra equipment necessary. VECTOR allows unrestricted, 360-degree movement, with a full 7 ft radius. VECTOR works with any lead apron and adjusts to any desired height or weight. VECTOR is proudly manufactured in North America. Easy to use, easy to install, VECTOR offers an elegant solution to a real problem. Tollos is committed to Lightening the Load of Care.

theheart.org Medscape Cardiology
825 8th Ave. 11th Floor
New York, NY 10019
p 212-301-6700
e rbrodeur@x-po.ca
w www.medscape.com/cardiology
Medscape Cardiology is the leading online destination for physicians and healthcare professionals worldwide, offering the latest medical news and expert perspectives. The site provides essential point-of-care drug and disease information, and continuing medical education in a variety of engaging formats. For more than 25 years, we have focused on improving patient care by delivering comprehensive clinical information and resources essential to the medical community.

TIMI Study Group
350 Longwood Ave.
First Office Floor
Boston, MA 02115
p 617-959-4325
e lpaterson@bwh.harvard.edu
w www.timi.org
The Thrombolysis in Myocardial Infarction (TIMI) Study Group, an academic research organization, was formed in 1984 with support from the National Heart, Lung, and Blood Institute. Its initial goal was to compare the effects of the then-new thrombolytic agent, recombinant tissue plasminogen activator, with streptokinase. TIMI has remained active since then and has completed 60+ multicenter clinical trials. The TIMI network now collaborates with more than 1,000 separate sites in 45 countries on five continents. In addition to thrombolytic agents, TIMI has studied antithrombotic, antiplatelet, anti-ischemic, lipid lowering and anti-inflammatory drugs. TIMI has also established robust biomarker and pharmacogenetics programs, and has devised a panel of risk assessment scores that are widely used.
UPMC Heart and Vascular Institute  
**w** [www.upmc.com/services/heart-vascular](http://www.upmc.com/services/heart-vascular)

**W-Z**

**Wolters Kluwer**  
Two Commerce Square 2001 Market Street  
Philadelphia, PA 19103  
**p** 612-816-4429  
**e** customer.service@wolterskluwer.com  
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers, students and the next generation of health care providers. With a focus on clinical effectiveness, research and learning, safety and surveillance, and interoperability and data intelligence, our proven solutions drive effective decision-making and consistent outcomes across the continuum of care.

**World Heart Federation**  
32 Rue Des Malatrex  
Geneva, 1201 Switzerland  
**p** +41 22 807 03 26  
**e** celine.schulz@worldheart.org  
**w** [www.worldheart.org](http://www.worldheart.org)  
For four decades, the World Heart Federation has been leading the global fight against cardiovascular disease, bringing together the CVD community to drive the CVD agenda and help people live longer, better, more heart-healthy lives. We believe in a world where heart health for everyone is a fundamental human right.

**Yale University Pathology Labs**  
310 Cedar St.  
Clinic Building, Fifth Floor  
New Haven, CT 06510  
**p** 203-785-5215  
**e** stephanie.weirsman@yale.edu  
**w** [www.medicine.yale.edu/pathology](http://www.medicine.yale.edu/pathology)  
Yale Pathology Labs is a comprehensive anatomic pathology service with the internationally recognized teaching and research expertise of Yale University School of Medicine.

**ZOLL LifeVest**  
121 Gamma Drive  
Pittsburgh, PA 15238  
**w** [www.lifevest.zoll.com](http://www.lifevest.zoll.com)  
The ZOLL® LifeVest® wearable cardioverter defibrillator (WCD) is a treatment option for patients at risk of sudden cardiac death (SCD). Over more than two decades, LifeVest has provided protection to hundreds of thousands of patients and saved thousands of lives. LifeVest combines sudden cardiac death protection with actionable insight about your patient during cardiac recovery to help you achieve a range of treatment goals including, including protection during recovery, optimization of medical therapy, more productive telehealth and follow-up, and timely clinical interventions, from ablation to ICD selection. Designed to continuously monitor a patient’s heart, LifeVest detects certain life-threatening rapid heart rhythms, and automatically deliver a treatment shock to restore normal heart rhythm. In a typical situation, the entire event, from detecting a life-threatening rapid heart rhythm to automatically delivering a shock, occurs in about one minute.
Introducing AHA-TV, your source for Science News and Scientific Sessions highlights.

Check the #AHA21 home page for bonus video content throughout the meeting.
Product Categories

Associations

International Societies
European Society of Cardiology (ESC)
World Heart Federation

Professional Association
AHA Hands Only CPR
AHA Healthcare Business Solutions (ECC)
AHA International
AHA Quality Improvement (QORA)
AHA Research
AHA Scientific Journals
AHA Target: Aortic Stenosis
American College of Cardiology
European Society of Cardiology (ESC)
NEJM Group

Education

Certification and Recertification
AHA Hands Only CPR
AHA Healthcare Business Solutions (ECC)
AHA Quality Improvement (QORA)
American College of Cardiology

Education, Teaching Aids, CME
AHA Hands Only CPR
AHA Healthcare Business Solutions (ECC)
AHA Lifelong Learning
AHA Target: Aortic Stenosis
AHA/ASA Patient Health
American College of Cardiology
JAMA Network
Mayo Clinic
Med Learning Group
NEJM Group
Quest Diagnostics, Inc.
theheart.org/Medscape Cardiology

Hospital/Institution/Practice

Healthcare Facilities Design/Construction
Northwestern Medicine

Recruitment
Intermountain Healthcare
Mayo Clinic
Northwestern Medicine

Imaging

CV Imaging Equipment
FUJIFILM VisualSonics

Echocardiography Equipment
AHA Target: Aortic Stenosis
FUJIFILM VisualSonics

Information Technology

Electronic Health Records/Electronic Medical Records (EHR/EMR)
Omron
Quest Diagnostics, Inc.

Electronic Information Services and Equipment
Invitae

Physician Practice Services and Management
AHA Quality Improvement (QORA)
Invitae
Omron

Technology–Computer Hardware, Software and/or Patient Management Tools With Medical Applications
Omron

Medical Device

Therapeutics
SCIRENT Clinical Research and Science

Medical Devices

Arrhythmia Monitoring Equipment
Omron
ZOLL LifeVest

Blood Pressure Monitoring Equipment
Omron

Diagnostic Catheters and Devices
Medtronic

ECG Equipment
Omron
ZOLL Medical Corporation
External Defibrillators
ZOLL LifeVest
ZOLL Medical Corporation

Interventional - Other Percutaneous Endovascular and Cardiac Devices
Inari Medical
Medtronic
Tollas, Inc.

Invasive Monitoring and Testing
FUJIFILM VisualSonics

Mechanical Cardiac Support Devices, Percutaneous and LVADs
ZOLL Medical Corporation

Pacing and Rhythm Management Devices
Medtronic

Patient Temperature Management
BD

Prostheses, Valves, and Pumps
Edwards Lifesciences

Telemedicine
Invitae
ZOLL LifeVest

Medical Equipment

Clinical Laboratory and Testing Services
Invitae
Quest Diagnostics, Inc.
Yale University Pathology Labs

Patient Monitoring Systems
Omron
ZOLL Medical Corporation

Pharmaceuticals

Diagnostics Medications
AstraZeneca
Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation – Medical Information
SCIRENT Clinical Research and Science

Therapeutic Medications
Acceleron Pharma, Inc.
Alexion, AstraZeneca Rare Disease
Amarin Pharma, Inc.
Amgen
Amryt Pharma
AstraZeneca
Bayer
Boehringer Ingelheim/Lilly Commercial
Boehringer Ingelheim/Lilly Medical
BridgeBio, Inc.
Bristol Myers Squibb
Bristol Myers Squibb Medical
Cytokinetics
Esperion Therapeutics
Ionis Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc.
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Medical
Know Diabetes by Heart
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation – Medical Information
Novo Nordisk Medical
Novo Nordisk, Inc.
Pfizer
Pfizer Medical Affairs – Rare Disease
PhaseBio Introduces REVERSE-IT
Regeneron Pharmaceuticals, Inc.

Publications, Books and Journals
Wolters Kluwer
AHA Scientific Journals
European Society of Cardiology
JAMA Network
NEJM Group
Oxford University Press

Research

Clinical Trials
Acceleron Pharma, Inc.
Amgen
Cardiovascular Clinical Sciences Foundation
Intermountain Healthcare
National Heart, Lung and Blood Institute NHLBI
NEJM Group
Novo Nordisk Medical
Pfizer Medical Affairs – Rare Disease
SCIRENT Clinical Research and Science
TIMI Study Group

Market Research
AHA Hands Only CPR
CL Laboratory, LLC
Invitae
Exhibitors by Community

**Basic Science**

*Arteriosclerosis, Thrombosis and Vascular Biology*
- AHA International
- AHA Research
- AHA Target: Aortic Stenosis
- AHA/ASA Patient Health
- CL Laboratory, LLC
- FUJIFILM VisualSonics
- Intermountain Healthcare

*Cardiac Development, Structure and Function*
- AHA Healthcare Business Solutions (ECC)
- AHA Research
- AHA Target: Aortic Stenosis
- AHA/ASA Patient Health
- CL Laboratory, LLC
- Edwards Lifesciences
- FUJIFILM VisualSonics
- Kiniksa Pharmaceuticals
- Kiniksa Pharmaceuticals Medical
- ZOLL Medical Corporation

*Cellular Biology*
- AHA Research
- FUJIFILM VisualSonics

*Drug Discovery*
- AHA Research
- AstraZeneca
- CL Laboratory, LLC
- Esperion Therapeutics
- FUJIFILM VisualSonics
- Kiniksa Pharmaceuticals
- Kiniksa Pharmaceuticals Medical
- Med Learning Group

*Genetics and Genomics*
- AHA Research
- Intermountain Healthcare
- Invitae
- Med Learning Group
- Quest Diagnostics, Inc.

*Metabolism and Physiology*
- AHA Research
- CL Laboratory, LLC

*Signaling*
- AHA Research

**Clinical Science**

*Acute Coronary Syndromes*
- AHA International
- AHA Research
- American College of Cardiology
- AstraZeneca
- Intermountain Healthcare
- Kiniksa Pharmaceuticals
- Kiniksa Pharmaceuticals Medical
- Oxford University Press
- Quest Diagnostics, Inc.
- TIMI Study Group
- Tollos, Inc
- Yale University Pathology Labs
- ZOLL LifeVest
- ZOLL Medical Corporation

*Cardio Oncology*
- AHA Research
- American College of Cardiology
- CL Laboratory, LLC
- Intermountain Healthcare
- Tollos, Inc
- Yale University Pathology Labs

*Congenital Heart Disease and Pediatric Cardiology*
- AHA Research
- American College of Cardiology
- Intermountain Healthcare
- Invitae
- Janssen Pharmaceuticals, Inc.
- Medtronic
- Tollos, Inc
- Yale University Pathology Labs

*Electrophysiology and Arrhythmias*
- AHA Research
- American College of Cardiology
- Intermountain Healthcare
- Invitae
- Medtronic
- Tollos, Inc
- ZOLL LifeVest

*Heart Failure and Cardiomyopathies*
- Acceleron Pharma Inc.
- AHA International
- AHA Research
- AHA/ASA Patient Health
American College of Cardiology
AstraZeneca
BridgeBio, Inc.
Cardiovascular Clinical Sciences Foundation
CL Laboratory, LLC
Cytkinetics
Intermountain Healthcare
Invitae
Ionis Pharmaceuticals, Inc.
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Medical
Medtronic
Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation – Medical
Information
Nova Nordisk Medical
Oxford University Press
Pfizer Medical Affairs – Rare Disease
SCIRENT Clinical Research and Science
TIMI Study Group
Tollos, Inc
Yale University Pathology Labs
ZOLL LifeVest
ZOLL Medical Corporation

**Hypertension and Nephrology**
AHA Research
American College of Cardiology
AstraZeneca
Intermountain Healthcare
Medtronic
Quest Diagnostics, Inc.
Yale University Pathology Labs

**Imaging and Nuclear Medicine**
AHA Research
American College of Cardiology
Cardiovascular Clinical Sciences Foundation
Intermountain Healthcare
Tollos, Inc

**Interventional Treatments**
AHA International
AHA Research
American College of Cardiology
Cardiovascular Clinical Sciences Foundation
Edwards Lifesciences
Inari Medical
Intermountain Healthcare
Med Learning Group
Quest Diagnostics, Inc.
TIMI Study Group
Tollos, Inc
Yale University Pathology Labs

**Nursing Research and Clinical**
AHA Quality Improvement (QORA)
AHA Research
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Medical

**Pulmonary Hypertension and Critical Care**
Acceleron Pharma Inc.
AHA Research
American College of Cardiology
Janssen Pharmaceuticals, Inc.
TIMI Study Group

**Resuscitation Science Symposium**
AHA Get With The Guidelines
AHA Quality Improvement (QORA)
AHA Research
ZOLL Medical Corporation

**Stroke and Neuroscience**
AHA International
AHA Research
AHA/ASA Patient Health
Amarin Pharma, Inc.
AstraZeneca
Medtronic
Tollos, Inc
ZOLL Medical Corporation

**Surgery and Anesthesia**
AHA Research
Tollos, Inc

**Vascular Disease and Thrombosis**
AHA Research
AHA Target: Aortic Stenosis
Amarin Pharma, Inc.
American College of Cardiology
Esperion Therapeutics
TIMI Study Group
Tollos, Inc
Yale University Pathology Labs
Population Science

Cardiometabolic Health and Diabetes
AHA Research
AHA/ASA Patient Health
American College of Cardiology
Amryt Pharma
AstraZeneca
Esperion Therapeutics
Ionis Pharmaceuticals, Inc.
Know Diabetes by Heart
Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation – Medical Information
Novo Nordisk Inc
Quest Diagnostics, Inc.

Lifestyle and Behavioral Medicine
AHA Research
Amryt Pharma
Know Diabetes by Heart

Prevention Health and Wellness
AHA Hands Only CPR
AHA Healthcare Business Solutions (ECC)
AHA Research
AHA/ASA Patient Health
American College of Cardiology
Amryt Pharma
Intermountain Healthcare
Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation – Medical Information
Quest Diagnostics, Inc.

Go Red for Women (GRFW) and Special Population
AHA Hands Only CPR
AHA Healthcare Business Solutions (ECC)
AHA International
AHA Research
Amryt Pharma
Esperion Therapeutics
Medtronic
Quest Diagnostics, Inc.

Quality of Care and Outcomes
AHA Get With The Guidelines
AHA Hands Only CPR
AHA International
AHA Quality Improvement (QORA)
AHA Research
AHA Target: Aortic Stenosis
Amryt Pharma
Esperion Therapeutics
Know Diabetes by Heart

Health Tech
AHA Research
Amryt Pharma
Edwards Lifesciences
Thank you to our supporters

The American Heart Association is grateful for the continued support and generosity of the following companies.

Amarin Pharma, Inc.
Amgen, Inc.
Amryt Pharma PLC
AstraZeneca Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc
Boehringer Ingelheim Pharmaceuticals, Inc
BridgeBio Pharma
Bristol Myers Squibb Company
CSL Behring
Cytokinetics, Inc.
Esperion Therapeutics, Inc.
Houston Methodist DeBakey Heart & Vascular Center
Invitae
Ionis Pharmaceuticals
Janssen Pharmaceuticals, Inc.
Lilly USA, LLC
Medtronic
Merck & Co., Inc.
NorthEast Monitoring, Inc.
Novartis Pharmaceuticals Corporation
Pfizer, Inc.
PhaseBio Pharmaceuticals, Inc.
Planet Fitness, Inc.
Sanofi
Theheart.org/Medscape Cardiology
Wolters Kluwer

Educational support for AHA Scientific Sessions is provided by:

Abbott Laboratories
AstraZeneca Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc
Biosense Webster, Inc.
Cytokinetics, Inc.
Merck Sharp and Dohme Corp.
Pfizer, Inc.